IBDEI02A ; ; 18-NOV-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;NOV 18, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,2530,1,8,0)
 ;;=8^Leukemia Unspec in Relapse
 ;;^UTILITY(U,$J,358.3,2530,2)
 ;;=^336485
 ;;^UTILITY(U,$J,358.3,2531,0)
 ;;=208.10^^26^185^12
 ;;^UTILITY(U,$J,358.3,2531,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2531,1,1,0)
 ;;=1^208.10
 ;;^UTILITY(U,$J,358.3,2531,1,8,0)
 ;;=8^Chr Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,2531,2)
 ;;=^336871
 ;;^UTILITY(U,$J,358.3,2532,0)
 ;;=208.11^^26^185^11
 ;;^UTILITY(U,$J,358.3,2532,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2532,1,1,0)
 ;;=1^208.11
 ;;^UTILITY(U,$J,358.3,2532,1,8,0)
 ;;=8^Chr Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,2532,2)
 ;;=^267569
 ;;^UTILITY(U,$J,358.3,2533,0)
 ;;=208.12^^26^185^10
 ;;^UTILITY(U,$J,358.3,2533,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2533,1,1,0)
 ;;=1^208.12
 ;;^UTILITY(U,$J,358.3,2533,1,8,0)
 ;;=8^Chr Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,2533,2)
 ;;=^336486
 ;;^UTILITY(U,$J,358.3,2534,0)
 ;;=208.20^^26^185^53
 ;;^UTILITY(U,$J,358.3,2534,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2534,1,1,0)
 ;;=1^208.20
 ;;^UTILITY(U,$J,358.3,2534,1,8,0)
 ;;=8^Subacute Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,2534,2)
 ;;=^336872
 ;;^UTILITY(U,$J,358.3,2535,0)
 ;;=208.21^^26^185^52
 ;;^UTILITY(U,$J,358.3,2535,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2535,1,1,0)
 ;;=1^208.21
 ;;^UTILITY(U,$J,358.3,2535,1,8,0)
 ;;=8^Subacute Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,2535,2)
 ;;=^267572
 ;;^UTILITY(U,$J,358.3,2536,0)
 ;;=208.22^^26^185^51
 ;;^UTILITY(U,$J,358.3,2536,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2536,1,1,0)
 ;;=1^208.22
 ;;^UTILITY(U,$J,358.3,2536,1,8,0)
 ;;=8^Subacute Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,2536,2)
 ;;=^336487
 ;;^UTILITY(U,$J,358.3,2537,0)
 ;;=208.80^^26^185^38
 ;;^UTILITY(U,$J,358.3,2537,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2537,1,1,0)
 ;;=1^208.80
 ;;^UTILITY(U,$J,358.3,2537,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type w/o Rem
 ;;^UTILITY(U,$J,358.3,2537,2)
 ;;=^336873
 ;;^UTILITY(U,$J,358.3,2538,0)
 ;;=208.81^^26^185^37
 ;;^UTILITY(U,$J,358.3,2538,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2538,1,1,0)
 ;;=1^208.81
 ;;^UTILITY(U,$J,358.3,2538,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type w/ Rem
 ;;^UTILITY(U,$J,358.3,2538,2)
 ;;=^267574
 ;;^UTILITY(U,$J,358.3,2539,0)
 ;;=208.82^^26^185^36
 ;;^UTILITY(U,$J,358.3,2539,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2539,1,1,0)
 ;;=1^208.82
 ;;^UTILITY(U,$J,358.3,2539,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type in Relap
 ;;^UTILITY(U,$J,358.3,2539,2)
 ;;=^336488
 ;;^UTILITY(U,$J,358.3,2540,0)
 ;;=209.00^^26^185^25
 ;;^UTILITY(U,$J,358.3,2540,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2540,1,1,0)
 ;;=1^209.00
 ;;^UTILITY(U,$J,358.3,2540,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Sm Intestine
 ;;^UTILITY(U,$J,358.3,2540,2)
 ;;=^336721
 ;;^UTILITY(U,$J,358.3,2541,0)
 ;;=209.01^^26^185^22
 ;;^UTILITY(U,$J,358.3,2541,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2541,1,1,0)
 ;;=1^209.01
 ;;^UTILITY(U,$J,358.3,2541,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Duodenum
 ;;^UTILITY(U,$J,358.3,2541,2)
 ;;=^336490
 ;;^UTILITY(U,$J,358.3,2542,0)
 ;;=209.02^^26^185^24
 ;;^UTILITY(U,$J,358.3,2542,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2542,1,1,0)
 ;;=1^209.02
 ;;^UTILITY(U,$J,358.3,2542,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Jejunum
 ;;^UTILITY(U,$J,358.3,2542,2)
 ;;=^336491
 ;;^UTILITY(U,$J,358.3,2543,0)
 ;;=209.03^^26^185^23
 ;;^UTILITY(U,$J,358.3,2543,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2543,1,1,0)
 ;;=1^209.03
 ;;^UTILITY(U,$J,358.3,2543,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Ileum
 ;;^UTILITY(U,$J,358.3,2543,2)
 ;;=^336492
 ;;^UTILITY(U,$J,358.3,2544,0)
 ;;=204.00^^26^186^1
 ;;^UTILITY(U,$J,358.3,2544,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2544,1,1,0)
 ;;=1^204.00
 ;;^UTILITY(U,$J,358.3,2544,1,8,0)
 ;;=8^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,2544,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,2545,0)
 ;;=204.01^^26^186^3
 ;;^UTILITY(U,$J,358.3,2545,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2545,1,1,0)
 ;;=1^204.01
 ;;^UTILITY(U,$J,358.3,2545,1,8,0)
 ;;=8^ALL,in Remission
 ;;^UTILITY(U,$J,358.3,2545,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,2546,0)
 ;;=204.10^^26^186^5
 ;;^UTILITY(U,$J,358.3,2546,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2546,1,1,0)
 ;;=1^204.10
 ;;^UTILITY(U,$J,358.3,2546,1,8,0)
 ;;=8^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,2546,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,2547,0)
 ;;=204.11^^26^186^7
 ;;^UTILITY(U,$J,358.3,2547,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2547,1,1,0)
 ;;=1^204.11
 ;;^UTILITY(U,$J,358.3,2547,1,8,0)
 ;;=8^CLL,in Remission
 ;;^UTILITY(U,$J,358.3,2547,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,2548,0)
 ;;=201.90^^26^186^11
 ;;^UTILITY(U,$J,358.3,2548,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2548,1,1,0)
 ;;=1^201.90
 ;;^UTILITY(U,$J,358.3,2548,1,8,0)
 ;;=8^Hodgkin's Lymphoma,Unspec Type
 ;;^UTILITY(U,$J,358.3,2548,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,2549,0)
 ;;=202.00^^26^186^19
 ;;^UTILITY(U,$J,358.3,2549,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2549,1,1,0)
 ;;=1^202.00
 ;;^UTILITY(U,$J,358.3,2549,1,8,0)
 ;;=8^Lymphoma,Low-Grade (Nodular)
 ;;^UTILITY(U,$J,358.3,2549,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,2550,0)
 ;;=200.20^^26^186^16
 ;;^UTILITY(U,$J,358.3,2550,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2550,1,1,0)
 ;;=1^200.20
 ;;^UTILITY(U,$J,358.3,2550,1,8,0)
 ;;=8^Lymphoma,Burkitts
 ;;^UTILITY(U,$J,358.3,2550,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,2551,0)
 ;;=202.10^^26^186^29
 ;;^UTILITY(U,$J,358.3,2551,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2551,1,1,0)
 ;;=1^202.10
 ;;^UTILITY(U,$J,358.3,2551,1,8,0)
 ;;=8^Mycosis Fungoides
 ;;^UTILITY(U,$J,358.3,2551,2)
 ;;=^80360
 ;;^UTILITY(U,$J,358.3,2552,0)
 ;;=273.3^^26^186^21
 ;;^UTILITY(U,$J,358.3,2552,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2552,1,1,0)
 ;;=1^273.3
 ;;^UTILITY(U,$J,358.3,2552,1,8,0)
 ;;=8^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,2552,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,2553,0)
 ;;=203.00^^26^186^28
 ;;^UTILITY(U,$J,358.3,2553,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2553,1,1,0)
 ;;=1^203.00
 ;;^UTILITY(U,$J,358.3,2553,1,8,0)
 ;;=8^Multiple Myeloma,W/O Remission
 ;;^UTILITY(U,$J,358.3,2553,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,2554,0)
 ;;=203.01^^26^186^27
 ;;^UTILITY(U,$J,358.3,2554,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2554,1,1,0)
 ;;=1^203.01
 ;;^UTILITY(U,$J,358.3,2554,1,8,0)
 ;;=8^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,2554,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,2555,0)
 ;;=202.40^^26^186^8
 ;;^UTILITY(U,$J,358.3,2555,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2555,1,1,0)
 ;;=1^202.40
 ;;^UTILITY(U,$J,358.3,2555,1,8,0)
 ;;=8^Hairy-Cell Leukemia
 ;;^UTILITY(U,$J,358.3,2555,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,2556,0)
 ;;=200.10^^26^186^18
 ;;^UTILITY(U,$J,358.3,2556,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2556,1,1,0)
 ;;=1^200.10
 ;;^UTILITY(U,$J,358.3,2556,1,8,0)
 ;;=8^Lymphoma,Int/High (Diffuse)
 ;;^UTILITY(U,$J,358.3,2556,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,2557,0)
 ;;=273.1^^26^186^25
 ;;^UTILITY(U,$J,358.3,2557,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2557,1,1,0)
 ;;=1^273.1
 ;;^UTILITY(U,$J,358.3,2557,1,8,0)
 ;;=8^Monoclon Paraproteinemia
 ;;^UTILITY(U,$J,358.3,2557,2)
 ;;=^78888
 ;;^UTILITY(U,$J,358.3,2558,0)
 ;;=238.79^^26^186^20
 ;;^UTILITY(U,$J,358.3,2558,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2558,1,1,0)
 ;;=1^238.79
 ;;^UTILITY(U,$J,358.3,2558,1,8,0)
 ;;=8^Lymphoproliferat Dis
 ;;^UTILITY(U,$J,358.3,2558,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,2559,0)
 ;;=202.90^^26^186^17
 ;;^UTILITY(U,$J,358.3,2559,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2559,1,1,0)
 ;;=1^202.90
 ;;^UTILITY(U,$J,358.3,2559,1,8,0)
 ;;=8^Lymphoma,Diffuse,Unspec Site
 ;;^UTILITY(U,$J,358.3,2559,2)
 ;;=^267504
 ;;^UTILITY(U,$J,358.3,2560,0)
 ;;=200.30^^26^186^23
 ;;^UTILITY(U,$J,358.3,2560,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2560,1,1,0)
 ;;=1^200.30
 ;;^UTILITY(U,$J,358.3,2560,1,8,0)
 ;;=8^Marginal Zone Lymphoma
 ;;^UTILITY(U,$J,358.3,2560,2)
 ;;=^335296
 ;;^UTILITY(U,$J,358.3,2561,0)
 ;;=200.40^^26^186^22
 ;;^UTILITY(U,$J,358.3,2561,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2561,1,1,0)
 ;;=1^200.40
 ;;^UTILITY(U,$J,358.3,2561,1,8,0)
 ;;=8^Mantle Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,2561,2)
 ;;=^335297
 ;;^UTILITY(U,$J,358.3,2562,0)
 ;;=200.50^^26^186^32
 ;;^UTILITY(U,$J,358.3,2562,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2562,1,1,0)
 ;;=1^200.50
 ;;^UTILITY(U,$J,358.3,2562,1,8,0)
 ;;=8^Prim CNS Lymphoma
 ;;^UTILITY(U,$J,358.3,2562,2)
 ;;=^335298
 ;;^UTILITY(U,$J,358.3,2563,0)
 ;;=200.60^^26^186^4
 ;;^UTILITY(U,$J,358.3,2563,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2563,1,1,0)
 ;;=1^200.60
 ;;^UTILITY(U,$J,358.3,2563,1,8,0)
 ;;=8^Anaplastic Large Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,2563,2)
 ;;=^335299
 ;;^UTILITY(U,$J,358.3,2564,0)
 ;;=200.70^^26^186^13
 ;;^UTILITY(U,$J,358.3,2564,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2564,1,1,0)
 ;;=1^200.70
 ;;^UTILITY(U,$J,358.3,2564,1,8,0)
 ;;=8^Large Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,2564,2)
 ;;=^335300
 ;;^UTILITY(U,$J,358.3,2565,0)
 ;;=200.80^^26^186^31
 ;;^UTILITY(U,$J,358.3,2565,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2565,1,1,0)
 ;;=1^200.80
 ;;^UTILITY(U,$J,358.3,2565,1,8,0)
 ;;=8^Oth Named Variants
 ;;^UTILITY(U,$J,358.3,2565,2)
 ;;=^176827
 ;;^UTILITY(U,$J,358.3,2566,0)
 ;;=201.00^^26^186^9
 ;;^UTILITY(U,$J,358.3,2566,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2566,1,1,0)
 ;;=1^201.00
 ;;^UTILITY(U,$J,358.3,2566,1,8,0)
 ;;=8^Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,2566,2)
 ;;=^265557
 ;;^UTILITY(U,$J,358.3,2567,0)
 ;;=201.10^^26^186^10
 ;;^UTILITY(U,$J,358.3,2567,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2567,1,1,0)
 ;;=1^201.10
 ;;^UTILITY(U,$J,358.3,2567,1,8,0)
 ;;=8^Hodgkin's Granuloma
 ;;^UTILITY(U,$J,358.3,2567,2)
 ;;=^58273
 ;;^UTILITY(U,$J,358.3,2568,0)
 ;;=201.20^^26^186^12
 ;;^UTILITY(U,$J,358.3,2568,1,0)
 ;;=^358.31IA^8^2
